All In Biotech

Drug Trial Radar · NCT05958121

IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific T Cell-Engaging Receptor Molecule (TCER®) Targeting PRAME, as Monotherapy or in Combination With a Checkpoint Inhibitor in Patients With Recurrent and/or Refractory Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Aug 9, 2023

Primary completion

Sep 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Immatics Biotechnologies GmbHIndustry
Sponsor type
Industry
First posted
Jul 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA402 in patients with recurrent and/or refractory solid tumors. Primary objectives: * To determine the maximum tolerated doses and/or recommended doses for extensions for IMA402 as monotherapy and in combination with pembrolizumab (Phase Ia) * To characterize the safety and tolerability of IMA402 as monotherapy and in combination (Phase I/II) * To evaluate anti-tumor activity of IMA402 as monotherapy and in combination (Phase II) Secondary objectives: * To evaluate the initial anti-tumor activity of IMA402 as monotherapy and in combination (Phase I) * To evaluate anti-tumor activity of IMA402 as monotherapy and in combination (Phase II) * To describe the PK of IMA402 as monotherapy and in combination (Phase I/II)

Conditions

  • Refractory Cancer
  • Recurrent Cancer
  • Solid Tumor, Adult
  • Cancer

Interventions

  • IMA402Drug

    IV infusions

  • IMA402 and checkpoint inhibitorDrug

    IMA402 IV infusions and checkpoint inhibitor

  • IMA402 and chemotherapyDrug

    IMA402 IV infusions and chemotherapy

  • IMA402 and IMA401Drug

    IMA402 and IMA401 IV infusions

  • IMA402 and monoclonal antibodyDrug

    IMA402 IV infusions and monoclonal antibody

  • IMA402 and chemotherapy +/- monoclonal antibodyDrug

    IMA402 IV infusions and chemotherapy +/- monoclonal antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I: Number of patients with dose limiting toxicities (DLTs)Time frame: 24 months
  2. Phase I/II: Number of patients with treatment-emergent adverse events (TEAEs)Time frame: 40 months
  3. Phase I/II: Number of patients with serious TEAEsTime frame: 40 months
  4. Phase I/II: Frequency of dose interruptions and reductions, permanent discontinuationsTime frame: 40 months
  5. Phase I/II: Duration of dose interruptions and reductions, permanent discontinuationsTime frame: 40 months
  6. Phase II: Overall response rate (ORR) based on best overall response (BOR) of complete response (CR) and partial response (PR) locally assessed using Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1)Time frame: 40 months

Locations

29 sites in 2 countries. Site status is shown where the registry gives one.

  • Universitaetsklinikum Heidelberg AöR

    Heidelberg, Baden-Wurttemberg, Germany · Recruiting

  • Thoraxklinik Heidelberg gGmbH

    Heidelberg, Baden-Wurttemberg, Germany · Recruiting

  • Universitaetsklinikum Mannheim GmbH

    Mannheim, Baden-Wurttemberg, Germany · Recruiting

  • Universitaetsklinikum Tuebingen AöR

    Tübingen, Baden-Wurttemberg, Germany · Recruiting

  • Universitaetsklinikum Ulm AöR

    Ulm, Baden-Wurttemberg, Germany · Recruiting

  • Universitaetsklinikum Erlangen AöR

    Erlangen, Bavaria, Germany · Recruiting

  • Klinikum Nürnberg

    Nuremberg, Bavaria, Germany · Completed

  • Universitaetsklinikum Regensburg

    Regensburg, Bavaria, Germany · Recruiting

  • Universitaetsklinikum Wuerzburg AöR

    Würzburg, Bavaria, Germany · Recruiting

  • Goethe University Frankfurt

    Frankfurt am Main, Hesse, Germany · Recruiting

  • Justus-Liebig-Universitaet Giessen

    Giessen, Hesse, Germany · Recruiting

  • Philipps-Universitaet Marburg

    Marburg, Hesse, Germany · Recruiting

  • Sana Klinikum Offenbach GmbH

    Offenbach, Hesse, Germany · Not yet recruiting

  • Elbe Kliniken Stade- Buxtehude Elbe Klinikum Buxtehude gGmbH

    Buxtehude, Lower Saxony, Germany · Recruiting

  • Universitaetsmedizin Goettingen

    Göttingen, Lower Saxony, Germany · Not yet recruiting

  • Universitaetsklinikum Bonn AöR

    Bonn, North Rhine-Westphalia, Germany · Recruiting

  • Marien Hospital Duesseldorf GmbH

    Düsseldorf, North Rhine-Westphalia, Germany · Recruiting

  • KEM I Evang. Kliniken Essen-Mitte gGmbH

    Essen, North Rhine-Westphalia, Germany · Recruiting

  • Universitaetsklinikum Essen AöR

    Essen, North Rhine-Westphalia, Germany · Recruiting

  • Johannes Wesling Klinikum Minden

    Minden, North Rhine-Westphalia, Germany · Recruiting

  • Universitaet Muenster

    Münster, North Rhine-Westphalia, Germany · Not yet recruiting

  • Klinikum Chemnitz gGmbH

    Chemnitz, Saxony, Germany · Completed

  • Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöR

    Dresden, Saxony, Germany · Recruiting

  • University Of Leipzig

    Leipzig, Saxony, Germany · Recruiting

  • Universitaetsklinikum Magdeburg AöR

    Magdeburg, Saxony-Anhalt, Germany · Recruiting

  • Universitair Medisch Centrum Groningen

    Groningen, Netherlands · Recruiting

  • Universitair Medisch Centrum Utrecht

    Utrecht, Netherlands · Recruiting

  • Antoni von Leeuwenhoek- Netherlands Cancer Institute

    Amsterdam, North Holland, Netherlands · Recruiting

  • Leiden Universitair Medisch Centrum

    Leiden, South Holland, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.